Scisparc Ltd
SPRC
View Detailed Chart
4.770USD
+0.120+2.58%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
238.30KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.58%
5 Days
+163.54%
1 Month
+5.76%
6 Months
+1335.88%
Year to Date
+1225.00%
1 Year
+1609.68%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.31M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 142.44.
Fairly Valued
The company’s latest PE is -2.87, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.89K shares, decreasing 42.34% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 2.07K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.65.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Ticker SymbolSPRC
CompanyScisparc Ltd
CEOMr. Amitay Weiss
Websitehttps://scisparc.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
